Additional information
by Lane B. II Scheiber (Author), Lane B. Scheiber Scd (Author)
The world is on fire, threatened by a global pandemic brought on by COVID-19. This virulent viral pathogen has rapidly infected every continent across the globe and has spread misery and death in its wake. COVID-19 is very efficient, carrying in its genetic code the instructions to construct its own personal replication machinery. This virus is very effective at copying itself, but does so with a relatively high rate of mutation to the genetic code. Given Coronavirus exhibits a frequent rate of alteration to its state, resulting in an elusive adversary, which makes treating with traditional vaccines an ongoing challenge. Fighting back with novel mRNA therapies, which can be rapidly redesigned, may offer an effective broad-spectrum therapeutic armamentarium to combat Coronavirus. Modification of the native human CD8 cell surface receptor to alert the immune system to the possible presence of the COVID-19, can result in early development of antibodies to target the pathogen. But taking the fight directly to the virus, to stop the infection in an afflicted person, is the next necessary technologic leap in pharmaceutical medicine. Redesigning native human transcription factors to create a hunter-killer protein to neutralize the COVID-19 genome is the next critical innovation necessary to eradicate viral pandemics. Cultivating a cure to counteract viral infections such as Coronavirus is now more essential than ever. Ebola, a devastatingly hostile viral infection, sits lurking, in wait. At the point Ebola evolves into an airborne viral entity, the consequences of such a noxious global pandemic will be horrific. The time is now, to secure versatile and effective vaccines and devise an effective cure to stop rampant viral infections, such as Coronavirus and Ebola.
